Pacific Biosciences of California, Inc.
PACB
$1.33
$0.064.72%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Revenue | 3.89% | -10.72% | -17.35% | -23.99% | -23.19% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 3.89% | -10.72% | -17.35% | -23.99% | -23.19% |
| Cost of Revenue | 6.15% | -11.92% | -15.70% | -17.83% | -22.19% |
| Gross Profit | -1.90% | -7.75% | -21.38% | -38.09% | -25.65% |
| SG&A Expenses | -24.40% | -8.86% | -1.63% | 6.95% | 11.54% |
| Depreciation & Amortization | 1,248.35% | 1,269.69% | 1,674.80% | 2,513.38% | 236.60% |
| Other Operating Expenses | 726.25% | 47.44% | 47.44% | 47.44% | -70.95% |
| Total Operating Expenses | 56.87% | 56.58% | 53.45% | 59.56% | -8.12% |
| Operating Income | -82.75% | -93.88% | -94.82% | -113.10% | -1.61% |
| Income Before Tax | -76.41% | -27.41% | -27.80% | -113.33% | 2.71% |
| Income Tax Expenses | 0.63% | 160.17% | 100.43% | 100.12% | 102.77% |
| Earnings from Continuing Operations | -76.34% | -27.75% | -31.46% | -121.54% | -1.02% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -76.34% | -27.75% | -31.46% | -121.54% | -1.02% |
| EBIT | -82.75% | -93.88% | -94.82% | -113.10% | -1.61% |
| EBITDA | 29.28% | 19.84% | 19.13% | 7.70% | 5.66% |
| EPS Basic | -60.91% | -16.29% | -19.63% | -100.76% | 5.92% |
| Normalized Basic EPS | -67.78% | -79.58% | -79.60% | -97.80% | 3.17% |
| EPS Diluted | -61.12% | -16.39% | -19.47% | -100.92% | 5.87% |
| Normalized Diluted EPS | -71.51% | -77.41% | -77.52% | -95.66% | 5.27% |
| Average Basic Shares Outstanding | 9.28% | 9.14% | 8.35% | 8.00% | 8.25% |
| Average Diluted Shares Outstanding | 6.95% | 11.35% | 10.60% | 10.30% | 10.60% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |